Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in... Key PointsQuestionIn statin-treated patients at high cardiovascular risk with elevated triglyceride levels and low levels of high-density lipoprotein cholesterol treated with ω-3 fatty acids, are achieved levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) associated with cardiovascular outcomes? FindingsIn a secondary analysis of a randomized clinical trial studying a carboxylic acid formulation of ω-3 fatty acids, plasma levels of EPA and DHA were measured 12 months after randomization in 10 382 patients. There was no association between achieved or change in level of either ω-3 fatty acid and major adverse cardiovascular events. MeaningThese findings do not support the concept that achieving higher EPA plasma levels through pharmacological means reduces adverse cardiovascular outcomes, nor were higher DHA levels associated with harm. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Loading next page...
 
/lp/american-medical-association/association-between-achieved-3-fatty-acid-levels-and-major-adverse-vO69SySbYf

References (17)

Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2021.1157
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionIn statin-treated patients at high cardiovascular risk with elevated triglyceride levels and low levels of high-density lipoprotein cholesterol treated with ω-3 fatty acids, are achieved levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) associated with cardiovascular outcomes? FindingsIn a secondary analysis of a randomized clinical trial studying a carboxylic acid formulation of ω-3 fatty acids, plasma levels of EPA and DHA were measured 12 months after randomization in 10 382 patients. There was no association between achieved or change in level of either ω-3 fatty acid and major adverse cardiovascular events. MeaningThese findings do not support the concept that achieving higher EPA plasma levels through pharmacological means reduces adverse cardiovascular outcomes, nor were higher DHA levels associated with harm.

Journal

JAMA CardiologyAmerican Medical Association

Published: Aug 16, 2021

There are no references for this article.